Residual IDH1-Mutant Tumor Cell Quantification Study for Glioma
This study is looking at a new way to detect remaining tumor cells during surgery for glioma, a type of brain tumor. It uses an investigational device called UR-ddPCR to quickly check for IDH1-mutant tumor cells right after a tumor is removed. If these cells are found, it can help guide surgeons to remove more tumor in real-time. You might be able to join if you are 18 or older, have a newly diagnosed glioma with features of an IDH-mutant tumor, and are scheduled for surgery at NYU Langone Health. The study aims to see how long patients live without their disease getting worse (Progression-Free Survival) for up to three years after the procedure. The current recruitment status is unclear.
- Study design
- This is a single-site study involving about 105 participants. It is an interventional study, meaning participants will receive a specific intervention.
- What's involved
- The investigational UR-ddPCR assay will be performed on tissue collected during your scheduled surgical visit.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for Progression-Free Survival for up to three years after the procedure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Residual IDH1-Mutant Tumor Cell Quantification Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Daniel Orringer, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Progression-Free Survival (PFS)Up to Year 3 Post-Procedure
PFS is defined as the time from surgery to the time of the first MRI demonstrating radiographic progression (using Response Assessment in Neuro-Oncology \[RANO\] criteria) or death due to any cause (whichever occurs earlier).